Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMany people notice their face looks visibly different after losing weight on semaglutide — cheekbones appear more defined, puffiness around the jaw softens, and the overall contour shifts. These changes are a direct result of fat loss across the whole body, including the face, which tends to show changes earlier than many people expect. Semaglutide is a prescription-only medicine, so any treatment involves a clinical assessment before a prescriber decides whether it is suitable for you. What follows is an honest account of what the evidence and clinical experience tell us about facial changes during Wegovy treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Imagine you've been on Wegovy for around six months. The scale has moved, your clothes fit differently, and one morning you catch your reflection and notice your face looks genuinely different to the one in your phone from last spring. That's not unusual. The face holds subcutaneous fat deposits around the cheeks, jaw, under the chin and the temples, and as the body draws down its overall fat stores, those areas reduce alongside everything else.
Clinical trial data for semaglutide 2.4mg, published in the STEP 1 trial in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks. At that scale of loss, facial changes are almost always perceptible. A person starting at 100kg who loses 15kg will very likely see a measurable reduction in facial fullness, basic geometry, not mystery.
The timing varies. Some people report facial slimming within the first few weeks, particularly around the jaw. Others see it mainly after the three-month mark, once total loss exceeds a threshold where their body's fat distribution starts to shift noticeably in the face. There's no single rule. Age, genetics, where fat was distributed to begin with, all of it plays in. If you're curious how results tend to develop across the first months generally, the before and after overview covers the broader arc of change.
Search for 'semaglutide face before and after' and you'll find two quite different kinds of posts: people delighted that their jaw has reappeared, and others worried their face looks gaunt or aged. Both experiences are real, and they're worth taking seriously.
Significant or rapid fat loss can reduce the volume of subcutaneous fat that gives the mid-face its structure. The result, in some people, is a hollowed appearance around the cheeks or temples, sometimes called 'Wegovy face' in the popular press, though that phrase doesn't appear in any clinical literature. This is not unique to semaglutide; it's a known consequence of substantial weight loss through any means. The NHS patient information on semaglutide doesn't list facial hollowing as a side effect, because clinically it isn't one, it's an aesthetic consequence of fat reduction, not a pharmacological effect of the medicine itself.
Whether this outcome is welcome or unwelcome is genuinely individual. People in their 30s with good skin elasticity often find the result flattering. People in their 50s or 60s with less elastic skin may find the change more mixed. Skin laxity around the chin and jaw (often described as 'jowling') is also possible after significant loss. Slower titration and pausing at lower doses while the body adapts can sometimes soften the pace of facial change; that's a conversation to have with your prescriber.
For a sense of how results vary specifically by sex, the before and after for men page looks at some of those patterns in more detail.
Before-and-after photographs circulate widely online. They're persuasive. They're also not clinical data. Lighting, angle, camera distance and image editing all affect what a face appears to do. The STEP 1 trial enrolled over 1,900 adults and measured outcomes rigorously over 68 weeks, and even that data gives you averages, not a guarantee of any individual's result.
What the evidence does tell us: most people on semaglutide 2.4mg lost meaningful weight over the trial period, with the majority of participants losing at least 5% of body weight. Facial changes at that level of loss are typical but not universal. The people least likely to notice pronounced facial change are those who started treatment with less facial fullness to begin with, or who lose weight more gradually.
For context on how the first month's results tend to compare to later ones, before and after at one month sets realistic expectations for that early window. And if you're trying to understand when results tend to become visible, how long Wegovy takes to work walks through the clinical timeline honestly.
One thing worth knowing before you start: a prescriber reviews your consultation the same day it arrives, a real clinician reading your answers, not software processing a form. If facial skin laxity or the pace of change is a concern, it's exactly the kind of thing to raise at that point, and if you're wondering how long it takes to get approved for Wegovy, that process is quicker than many people expect. You can also read more about Wegovy as a treatment before deciding whether to proceed. If you're ready to see whether it's clinically appropriate for you, start your free consultation, it costs nothing, and there's no obligation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.